Standard BioTools Inc.
Income Statement
| Line Item | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $22.5M | $45.5M | $28.2M | $25.4M | $27.7M | $25.1M | $27.0M | $25.6M |
| Cost of Revenue | $12.1M | $21.4M | $14.8M | $14.2M | $14.1M | $12.8M | — | $16.4M |
| Gross Profit | $10.4M | $24.2M | $13.4M | $11.2M | $13.6M | $12.3M | — | $9.2M |
| Gross Margin | 46.1% | 53.1% | 47.6% | 44.0% | 49.2% | 48.9% | — | 36.0% |
| Operating Expenses | ||||||||
| Research & Development | $7.2M | $16.0M | $7.0M | $6.4M | $6.2M | $6.4M | $7.4M | $8.5M |
| SG&A Expense | $24.9M | $46.9M | $21.4M | $22.3M | $22.6M | $21.3M | $15.0M | $26.3M |
| Operating Income | $-30.3M | $-60.2M | $-21.4M | $-21.2M | $-17.4M | $-16.6M | $-21.1M | $-29.0M |
| Operating Margin | -134.5% | -132.2% | -75.9% | -83.5% | -63.1% | -66.1% | -78.1% | -113.2% |
| Interest Expense | — | — | $1.1M | $1.2M | $1.1M | $1.1M | $1.2M | $1.0M |
| Pretax Income | $-25.4M | $-32.0M | $-19.9M | $-20.9M | $-16.7M | $-16.6M | $-20.8M | $-30.1M |
| Income Tax Expense | $39.0K | $128.0K | $-162.0K | $50.0K | $301.0K | $263.0K | $70.0K | $-713.0K |
| Net Income | $-45.7M | $-32.2M | $-19.8M | $-21.0M | $-17.0M | $-16.8M | $-20.8M | $-29.4M |
| Net Margin | -203.3% | -70.6% | -70.2% | -82.8% | -61.6% | -67.1% | -77.1% | -114.7% |
| EPS (Basic) | $-0.03 | $-0.07 | $-0.06 | $-0.07 | $-0.06 | $-0.05 | $-0.06 | $-0.09 |
| EPS (Diluted) | $-0.03 | $-0.07 | $-0.06 | $-0.07 | $-0.06 | $-0.05 | $-0.06 | $-0.09 |
| Shares Outstanding (Basic) | 1.49B | 1.18B | 316.6M | 316.6M | 314.7M | 316.3M | 313.2M | 315.6M |
| Shares Outstanding (Diluted) | 1.49B | 1.18B | 316.6M | 316.6M | 314.7M | 316.3M | 313.2M | 315.6M |
| Dividends Per Share | — | — | — | — | — | — | — | — |